| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Internet and Businesses Online > Ecommerce > Process Visa/Master Card Transacations Directly with Visa/Master Card; Cut Out The Middle Man |
|
Just Other Articles - Process Visa/Master Card Transacations Directly with Visa/Master Card; Cut Out The Middle Man
Some businesses are not aware of hidden fees they are paying to process credit card transactions. Many businesses have not had anyone explain how credit card processing works. Businesses need to know how much they are really paying to proces According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product s credit card transactions. Many businesses do not know the difference between a portfolio manager and ISOs (Independent Sales Organizations) or MSPs(Merchant Service Providers). A new software program that analyzes merchant statements and c ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in n show how much businesses are overspending in fees, and who those fees are being paid to. Businesses need to know exactly how much they are paying Visa/Master Card plus how much they are paying the ISOs (Independent Sales Organizations) or M lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. SPs (Merchant Service Providers). Overspending is inherent within the traditional merchant service channels. To prevent overspending, Visa and Master Card suggest getting rid of the traditional channel. When Visa and Master Card began, the here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe created ISOs and MSPs to advertise, but now everyone knows who Visa and Master Card are, and they do not need advertising. These sales organizations created excess spending and added no real value to the businesses. In the beginning, these d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ales organizations allowed Visa and Master Card to get their services distributed; now Visa and Master Card are global monopolies and no longer need these types of sales channels. This problem has grown out of control; businesses are going un ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc der, financially being destroyed by these sales organizations. Approximately 14 million businesses in America alone accept credit cards; they are forced to accept credit cards because of the increase in cardholders. This results in annual o easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ercharges of approximately 100 billion dollars. ISOs/MSPs charge every business a percentage and transactions fees on top of what Visa and Master Card charge, along with fees that are not visible. Every time an error is processed, a business nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically pays a higher rate for that transaction than what they were promised. Different types of cards are charged different rates. Many businesses do not ask/know what rates they are being charged for a corporate credit card, signature card, reward and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s card, or a debit card. Visa and Master Cards are the bank associations. The bank association is a hollow shell which holds issuing banks and acquiring banks. Issuing banks issue credit cards. Acquiring banks process or fund all transacti ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ns; they are Visa and Master Card’s processing center. As a business owner, I would rather pay wholesale processing versus retail processing. What is the difference between wholesale versus retail credit card processing? What makes up retai ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a pricing is wholesale plus traditional merchant channel charges and extra hidden fees. Wholesale pricing is Interchange / Dues - this is paid to the issuing banks for issuing the credit cards. Assessment fees - this is the portion of the dis dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod count fee that is paid directly to Visa and Master Card. Processing - this is paid to the acquiring banks for processing and funding all transactions. Where does your business stand in today's global market, are you paying wholesale or retai cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin to process your credit card transactions? Visa and Master Card are now working directly with a portfolio manager to help cut this incredible amount of overspending. A portfolio manager for Visa and Master Card will audit businesses statemen tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen s allowing them to see how much they are currently spending over wholesale. As a result, this provides an in-depth analysis on three months of merchant statements. This analysis tells: what is being charged and how it affects overhead, what t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel wholesale pricing truly is, and what net savings a business gains when accepted into this portfolio. The benefit of working with a portfolio manager equals wholesale rates versus retail rates on Visa and Master Card processing. Businesses ga ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust n the buying power of a larger business group by being in a portfolio. A portfolio manager provides accountability by providing periodic performance reviews to confirm client savings. A portfolio manager has proven they have been able to eli y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products inate an average of 15% to 45% in overall processing charges. They are presently working with businesses in 46 states and growing rapidly. They work directly with the acquiring bank and have the highest performing portfolio in the industry a . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de s a whole. Their turn over rate is 0%. The reason for this incredible turn over rate percentage is, businesses do not need to look beyond what they will receive from a portfolio manager. The business is receiving wholesale rates directly fr elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip m Visa and Master card. Most traditional merchant service channels have a 16% to 20% turnover rate each month. I suggest checking into a protfolio manager, to manager your online or offline credit card processing. What will your savings be tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Medical Billing - XA0 Record Fields 9 Through 17
|